Recently developed HIF-2α inhibitors PT2399 and PT2385 only have efficacy in specific renal cell carcinomas, but not in other types of cancer [19, 20, 53, 54]. This evidence concerns the gene EPAS1 and hereditary clear cell renal cell carcinoma.